Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jun 21, 2021 9:59am
83 Views
Post# 33419603

RE:RE:RE:in vivo clinical results

RE:RE:RE:in vivo clinical results

This will be an interesting presentation, not so much for thinking we will get any hard trial data (I would expect nothing more than a "...everything is on track, we are pleased with clinics, so far data collection all going as planned and no surprises, will have answers shortly and will commence part 2..." ), but it seems from the wording that LSA has helped them string together the key aspects and advantages of the approach in a punchier and more convincing way.  They lay out the reasons why this "could" be a seriously disrupting science that they own 100% of.  To me it seems more convincing and logical - maybe they are getting more confident about it as experienced outsiders see all the facts lining up and tell them to push the arguments forward.   Let's see if the management portion of the call is also lines of the themes they've incorporated in the PR.
 

if so, maybe we will finally Keep that U$4 handle going forward.   FTV - maybe your $5 level will be in sight for the summer.


muslix1 wrote:
the market dont like the news ...
people are nervous good sing

 

<< Previous
Bullboard Posts
Next >>